Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Glycosylated Hybrid Lipid Polymer Nanoparticles for Inhalable Co-Delivery of Docetaxel and Nintedanib in NSCLC

Usha Nayak – Professor, Pharmaceutics, Manipal College of Pharmaceutical Sciences; Sanjay Garg – Professor, Pharmaceutical Sciences, Adelaide University

    Poster Presenter(s)

  • Akanksha D. Dessai

    MPharm
    Manipal College of Pharmaceutical Sciences
    Margao, Goa, India

Introduction:

Non-small cell lung cancer (NSCLC) represents approximately 85% of lung cancer cases and remains associated with high mortality. Although Docetaxel (DTX) and Nintedanib (NTB) combination therapy improves clinical outcomes, systemic exposure and poor lung retention limit therapeutic benefit. This work investigates inhalable glycosylated hybrid lipid polymer nanoparticles (HLPNs) designed for controlled release, enhanced lung localization, and improved bioavailability of DTX and NTB (1,2).

Learning Objectives:

  • Describe usage of glycosylated hybrid lipid polymer nanoparticles for inhalable NSCLC therapy.
  • Demonstrate controlled release and computational diffusion studies in lung retention of DTX and NTB.
  • Evaluate the advantages of nanoparticle-based combination therapy over conventional delivery in NSCLC.